Wegovy
Semaglutide
What it is approved for, injection or tablet, and how prescribing works here.
Semaglutide (Wegovy)Fayetteville, NY, serving Syracuse
It depends on your plan and on the reason the drug is prescribed. Medicare, New York Medicaid and employer plans each follow their own rules, set out below with sources and dates.
By kind of coverage
Each row names its source and date. Patients should confirm medication coverage directly with their plan.
Wegovy and Zepbound by kind of coverage, as read on November 15, 2026
| Kind of coverage | What the source says | Where to check |
|---|---|---|
| Employer or individual plan regulated by New YorkID card says "fully insured" | No statement was found on the website of New York's Department of Financial Services (DFS), as of November 15, 2026, that these plans must cover weight-loss drugs, or that they need not. DFS says the phrase "fully insured coverage" on an ID card means the coverage follows New York law. | The plan's formulary: DFS says a plan must give it to you on request, including whether individual drugs are covered. |
| Self-funded employer planAlso called self-insured | DFS says that when an employer self-funds its coverage, an insurer may still process claims, but New York protections don't apply. | DFS says to check your ID card or contact your insurer or employer if you don't know what type of coverage you have. |
| Medicare Part DThe regular drug benefit | A CMS memo dated June 10, 2026 describes a GLP-1 used for weight loss as excluded from coverage under Medicare Part D. It names Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, and Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, as uses covered under the basic Part D benefit. | Your Part D plan: the memo says its utilization management requirements apply. |
| Medicare GLP-1 BridgeTemporary: July 1, 2026 to December 31, 2027 | On a page last modified July 13, 2026, CMS says this short-term demonstration gives eligible Part D beneficiaries access to certain GLP-1 drugs between July 1, 2026, and December 31, 2027, with a $50 copay. Medicare.gov lists Wegovy (injection or tablet) and Zepbound (KwikPen only) among the drugs covered, with requirements based on body mass index and certain health conditions. | The requirements are on Medicare.gov, Weight loss drugs. |
| New York MedicaidNYRx, the Medicaid pharmacy program | The September 2026 Medicaid Update lists drugs used for weight loss among the drug uses that are not reimbursable by New York State Medicaid. The NYRx Preferred Drug List, revised October 22, 2026, lists criteria for Wegovy with a diagnosis of cardiovascular disease and for Zepbound with a diagnosis of obstructive sleep apnea, including a body mass index of 40 or higher and a limit of two treatment attempts per lifetime. | The Drug Utilization Review section of the NYRx Preferred Drug List. |
| HSA or FSAHealth savings or flexible spending account | An IRS page last reviewed September 23, 2026 says expenses for medical care are eligible to be paid or reimbursed under an HSA or FSA. IRS Publication 502 (2025) counts amounts paid for prescribed medicines and drugs as medical expenses. | IRS Publication 502, and your account administrator. |
The reason for the prescription
Coverage varies widely by insurance plan and by the specific medication and indication. Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for chronic weight management in appropriate patients.
Indications are from the Wegovy prescribing information (revised June 2026) and the Zepbound prescribing information (revised August 2026), read November 15, 2026, and are shortened here.
Prior authorization
HealthCare.gov defines prior authorization as approval from a health plan that may be required before you get a service or fill a prescription in order for the service or prescription to be covered by your plan. We handle prior authorizations for eligible Lilly and Novo Nordisk medications.
HealthCare.gov adds that preauthorization isn't a promise your health insurance or plan will cover the cost.
For plans subject to New York law, DFS says, as read on November 15, 2026, that the decision generally comes within 3 business days for care you have not received yet, and within 72 hours if urgent.
For the Medicare GLP-1 Bridge, Medicare.gov says, as read on November 15, 2026, that the provider completes a prior authorization when requested and certifies that the drug is used as part of a lifestyle program that focuses on diet and exercise.
We do not bill insurance for visits; we are out of network. We provide superbills and supporting documentation. Patients should confirm medication coverage directly with their plan.
If a plan says no
For plans subject to New York law, DFS describes an internal appeal with the health plan, then an external appeal to DFS. The DFS pages show no date; the wording here is as read on November 15, 2026.
From the Department of Financial Services external appeal page and health insurance consumer page. A summary of the regulator's wording, not legal advice.
Without coverage
Medication cost is separate from the visits and depends on the medication, its form and your coverage. The visits here are self-pay, and we provide superbills.
We accept HSA and FSA cards, CareCredit and Cherry payment plans.
IRS Publication 502 (2025) says you can include in medical expenses amounts you pay to lose weight if it is a treatment for a specific disease diagnosed by a physician, such as obesity, hypertension, or heart disease. It says you can't if the purpose of the weight loss is the improvement of appearance, general health, or sense of well-being.
Your first visits are one complete package, $249, with no long-term contract. Pricing as of November 2026.
What the visits cost, and what they include, is on our weight loss cost in Syracuse page.
First visits
A free call first, then one complete evaluation in three parts. If a medication is appropriate, it is discussed at the provider visit, after your bloodwork is back.
Free, up to 30 minutes
A call with our team: how the program works, your questions and pricing. Nothing medical is decided on the call.
Part 1, with a nurse
Resting metabolic rate (RMR) testing, Tanita body-composition analysis including muscle mass, blood pressure and pulse ox, and an in-office blood draw. Recent bloodwork from your own doctor can be reviewed.
Part 2, about 60 minutes
A provider reviews your labs, medical history, medications, weight history, and previous treatment attempts. Together, you discuss whether a GLP-1, another medication, or a non-medication approach is most appropriate.
About 45 minutes
With our registered dietitian, to strategize your daily plan. Meal replacements are optional.
Ongoing
Regular follow-up visits monitor your progress, identify problems early, and adjust your plan along the way.
When you reach your goal, the focus changes from losing weight to maintaining it through our weight maintenance program.
Who treats you
Dr. Scinta founded the practice and directs the medical care. She works alongside nurse practitioners and a registered dietitian.





Questions
Short answers, each with its source.
For weight management, Medicare.gov says the temporary Medicare GLP-1 Bridge covers Wegovy, injection or tablet, starting July 1, 2026, for people who meet its requirements. A June 10, 2026 CMS memo names Wegovy prescribed to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight as a use covered under the basic Part D benefit, subject to the Part D plan's utilization management requirements.
Under the Medicare GLP-1 Bridge, which began July 1, 2026, Medicare.gov lists the Zepbound KwikPen only and says the program doesn't cover single-dose Zepbound vials or pens. A June 10, 2026 CMS memo names Zepbound prescribed for moderate to severe obstructive sleep apnea in adults with obesity as a use covered under the basic Part D benefit, subject to the Part D plan's utilization management requirements.
The September 2026 Medicaid Update lists drugs used for weight loss among the drug uses that are not reimbursable by New York State Medicaid. The NYRx Preferred Drug List, revised October 22, 2026, lists criteria for Wegovy with a cardiovascular disease diagnosis and for Zepbound with an obstructive sleep apnea diagnosis.
No statement was found on the website of New York's Department of Financial Services (DFS), as of November 15, 2026, that New York-regulated plans must cover weight-loss drugs, or that they need not. DFS says New York protections don't apply to self-funded employer coverage. The plan's own documents decide; ask your plan for its formulary.
HealthCare.gov defines it as approval from a health plan that may be required before you fill a prescription in order for the prescription to be covered by your plan. We handle prior authorizations for eligible Lilly and Novo Nordisk medications.
For plans subject to New York law, the state's Department of Financial Services (DFS) says, as read on November 15, 2026, that an external appeal application must be sent to DFS within 4 months from the date of the final adverse determination from your internal appeal with the health plan. The steps are under what happens if a plan says no.
We accept HSA and FSA cards, CareCredit and Cherry payment plans. An IRS page last reviewed September 23, 2026 says expenses for medical care are eligible to be paid or reimbursed under an HSA or FSA.
We do not bill insurance for visits; we are out of network. We can provide a superbill for you to submit.
Published by Medical Weight Loss of New York. Last updated . Educational information only; not a substitute for medical advice.
Location and hours
The office is at 6800 E Genesee St, Suite 1501, Fayetteville, NY 13066, on East Genesee Street minutes from I-481. It serves patients in Syracuse, Fayetteville, Manlius, DeWitt, East Syracuse, and across Central New York.
East Genesee Street, FayettevilleMinutes from I-481. Open the map for directions from where you are.
Telemedicine may be available for appropriate follow-up visits, but testing, laboratory work, body-composition measurement, and other parts of the program require in-office care.
Sources
Every coverage statement on this page comes from one of these public sources, read on November 15, 2026. Rules change; the linked pages are the current word.
Last updated .
Next step
A free call with our team, up to 30 minutes: how the program works, your questions, and pricing. Nothing medical is decided on the call.